Soluble interleukin-2 receptor in cancer.
Levels of serum sIL-2R (soluble interleukin-2 receptor) reflect the total amount of activated T lymphocytes in tumor infiltrating lymphocytes of cancer tissues and metastatic organs, because a part of alpha-chain of IL-2R is released into the bloodstream on the attachment of IL-2 (interleukin-2) to its specific IL-2R membrane. In most malignant diseases, elevated levels of serum sIL-2R are found, compare to normal control. Serum sIL-2R is a useful parameter for evaluating the disease stage and monitoring the disease progression during the post-treatment follow-up, though it is not an organ-specific parameter.
Murakami
Saburo
S
Department of Surgery, Saitama Medical School, Morohongo 38, Moyorama-machi, Iruma-gunn,Saitama, 350-0495, Japan. smurakam@saitama-med.ac.jp
D014408:Biomarkers, Tumor; D018450:Disease Progression; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007376:Interleukin-2 / Q000378:metabolism; D016246:Lymphocytes, Tumor-Infiltrating / Q000378:metabolism; D008297:Male; D009369:Neoplasms / Q000378:metabolism*; D015375:Receptors, Interleukin-2 / Q000097:blood* / Q000502:physiology*
D014408:Biomarkers, Tumor; D007376:Interleukin-2; D015375:Receptors, Interleukin-2